A regenerative-research digest · BPC-157 + TB-500
BPC-157 TB-500 is the two-peptide Wolverine blend, read across the published tissue-repair literature.
Two peptides, two mechanisms, one digest. We summarize what the preclinical record establishes for each constituent, mark every gap, and read the regulatory status first.
The Wolverine blend in one read
BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair pairing, marketed and discussed under the label "Wolverine." It is not a single chemical entity, and it is not an approved product. It is two distinct synthetic peptides — BPC-157 and a fragment of Thymosin Beta-4 — co-formulated and studied separately, never together in a controlled trial.
Both peptides have generated reproducible findings in animal models of tissue repair. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures [1]. The actin-binding fragment marketed as TB-500 derives from Thymosin Beta-4, the body's principal monomeric-actin sequestering molecule, whose structure with actin was solved at 2 Å [3]. What the blend does not have is a single controlled study of the two peptides given together — no synergy ratio, dose, or endpoint has been defined in the peer-reviewed record [1].
This page is the index. Each constituent leg of the blend is tracked separately below, and the deeper research findings for BPC-157 and TB-500 carry the full citation trail. For what reviewers and clinicians have published most recently, the BPC-157 TB-500 latest research page covers the 2024–2026 studies.
BPC-157 and TB-500: the two peptides in the Wolverine blend
The blend has two legs, and the design device on this site marks which is which.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, molecular weight approximately 1,419 Da, derived from a protein found in human gastric juice [1]. It supplies the blend's local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and drives the VEGFR2-Akt-eNOS pathway, and it sensitizes tendon fibroblasts via the growth-hormone receptor [2].
TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight approximately 889 Da, corresponding to residues 17–23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4 [5]. It supplies the blend's cytoskeletal and cell-migration signal: the LKKTETQ helix binds monomeric (G-) actin 1:1 and sequesters it, regulating the dynamics that drive cell migration and re-epithelialization [3].
One identity note runs through everything that follows. The 7-mer sold as TB-500 is not the molecule most of the efficacy literature was generated with — the overwhelming majority of "TB-500" data come from full-length Thymosin Beta-4 (approximately 4,963 Da), not the fragment [4].
BPC 157 TB 500 (unhyphenated spelling)
The blend is written several ways online — BPC-157 TB-500, BPC 157 TB 500, and BPC157 TB500 all refer to the same two-peptide pairing. The hyphenated forms are used throughout this digest for clarity, but the unhyphenated spellings name the identical constituents.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack." It is not a single chemical entity or an approved product, and it has no CAS number or molecular weight of its own — those identifiers exist only per constituent [1].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, supplying a cytoprotective and angiogenic signal [1]. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4, supplying a cytoskeletal and cell-migration signal [5]. They differ in size, sequence, origin, and mechanism.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide acting as a local cytoprotective and angiogenic signal; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting as a cytoskeletal and cell-migration signal [5]. They differ in size, sequence, origin, and mechanism — and only TB-500 traces back to a larger endogenous protein [4].
What is the BPC-157 and TB-500 blend used for in research?
It is studied in animal models for tissue repair: BPC-157 in tendon, ligament, muscle, and wound-healing models [1], and TB-500/Thymosin Beta-4 in wound, ligament, and cell-migration models [4]. There is no approved human indication for the blend [2].
The BPC-157 TB-500 stack rationale
The combination is rationalized as a two-mechanism pairing: a local angiogenic and cytoprotective signal from BPC-157, and an intracellular actin-sequestration signal from TB-500. The two are described as acting through complementary but largely non-overlapping pathways, which is the basis of the "synergy" claim [2].
Why is BPC-157 combined with TB-500?
They are described as acting through complementary, largely non-overlapping pathways: BPC-157 supplies a local angiogenic and cytoprotective signal via VEGFR2-Akt-eNOS [2], and TB-500 supplies an actin-sequestration signal that drives cell migration [3]. This pairing logic is the combination (synergy) rationale — a theoretical extrapolation, not a finding from a controlled combination study.
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The stack pairs a vascular and cytoprotective signal with a cytoskeletal migration signal, on the theory that repair benefits from both at once. BPC-157 acts through VEGFR2-Akt-eNOS and growth-hormone-receptor sensitization [2]; TB-500 acts through 1:1 G-actin sequestration [3]. The "synergy" is an extrapolation from each peptide's separate mechanism; no controlled combination study has demonstrated it [1].
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together. The 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [6]; synergy claims are extrapolations from each peptide's separately characterized mechanism [2].
How the two mechanisms are described
The two legs of the blend are studied through different machinery, and reading how the Wolverine blend works means reading two mechanisms, not one.
How does BPC-157 work compared to TB-500?
BPC-157 acts through VEGFR2-Akt-eNOS angiogenic and nitric-oxide signaling and growth-hormone-receptor sensitization of tendon fibroblasts [2], whereas TB-500 acts through G-actin sequestration and cytoskeletal remodeling [3]. The two are described as complementary, non-overlapping mechanisms [2].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric (G-) actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3]. Most efficacy data attributed to TB-500 were actually generated with full-length Thymosin Beta-4 [4].
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both are reported to promote angiogenesis by distinct routes in animal and cell models: BPC-157 via VEGFR2-Akt-eNOS up-regulation [2], and TB-500/Thymosin Beta-4 via endothelial migration [4]. This shared vascular thread is part of the combination rationale, though it is the one place the two mechanisms touch.